START (Study in Asia of the Combination of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib in Hepatocellular Carcinoma (HCC) Patients) Trial.

Trial Profile

START (Study in Asia of the Combination of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib in Hepatocellular Carcinoma (HCC) Patients) Trial.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2015

At a glance

  • Drugs Sorafenib (Primary) ; Doxorubicin
  • Indications Liver cancer
  • Focus Adverse reactions
  • Acronyms START
  • Sponsors Bayer HealthCare Pharmaceuticals
  • Most Recent Events

    • 15 Mar 2015 Status changed from active, no longer recruiting to completed according to results published in the International Journal of Cancer.
    • 04 Jan 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 12 Oct 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top